Accreditation Information

Description

The 22nd International Ultmann Chicago Lymphoma Symposium (IUCLS) is a continuation of an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.

The goal of this educational activity is to facilitate a forum for physicians, nurses, researchers, and other healthcare professionals to discuss biologic, diagnostic, and therapeutic aspects of Hodgkin and non-Hodgkin lymphoma.

This event gives opportunities for providers to explore vital information on clinical updates and research in order to ensure they are using the latest treatment options in their practice.

Target Audience

The target audience for this symposium is practicing oncologists, hematologists, advanced nurse practitioners, physician assistants, residents, fellows, nurses, pharmacists, and the other health professionals interested in the treatment and diagnosis of lymphoma.

Learning Objectives

• Assess clinical trial results of approved and investigational treatment strategies being studied in patients with indolent and aggressive subtypes of B-cell and T-cell non-Hodgkin lymphoma
• Compare and contrast the selection and sequencing of therapeutic approaches for the care of patients with newly diagnosed and relapsed/refractory Hodgkin lymphoma
• Evaluate the various patient and disease-related factors that may impact therapeutic decisions for patients with newly diagnosed and previously treated CLL/SLL
• Review approaches to the care of patients with rarer hematologic malignancies, including CNS lymphoma and Waldenstrom macroglobulinemia
• Identify and nurture strategies to enhance communication and collaboration with the entire multidisciplinary healthcare team during the continuum of care of patients with lymphoma

Accreditation and Credit Designation Statement:

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and Bio Ascend LLC. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 12 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

University of Chicago Medicine is accredited as a provider of continuing nursing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn 12 contact hours.

American Board of Internal Medicine MOC Part II Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 12 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other Participant Credit

Other participants will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.

Educational Grants/Commercial Support

Educational grant funding has been generously provided by: ADC Therapeutics, AstraZeneca, Incyte, Pfizer, Recordati Rare Diseases

Disclosure Declarations

As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone in a position to control content of an educational activity to disclose all financial relationships with any ineligible companies. This includes any entity whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. Financial relationships are relevant if financial relationship, in any amount exists between the person in control of content and an ineligible company during the past 24 months, and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. Mechanisms are in place to identify and mitigate any relevant financial relationships prior to the start of the activity.

Additionally, the University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Course Faculty

The following faculty and planners have disclosed that they have no relevant financial relationships with ACCME defined commercial interests in the past twelve months:

Pamela B. Allen, MD
Kirk Cahill, MD
Hunter C. Cochran, MD
Sandeep Dave, MD 
Kaitlin P. Kelly, PharmD, BCOP
Tara A. McCabe, FNP-BC
Neval Ozkaya, MD
Alexandra E. Rojek, MD
Girish Venkataraman, MD
Jane Winter, MD

Nancy Bartlett, MD receives institutional research funding from ADC Therapeutics, Autolus, BMS/Celgene, Forty Seven/Gilead, Genmab/AbbVie, Gilead, Janssen, Millennium, Pharmacyclics, Roche/Genentech, and Seattle Genetics. Dr. Bartlett serves on the advisory board for Genmab/AbbVie, Kite, Pfizer/SeaGen, and Roche/Genentech.

Ruemu Birhiray, MD receives institutional research funding from Genentech/Roche, Regeneron, Takeda, and Novartis, serves on the speakers bureau for Amgen Inc., Astellis, Puma Biotechnology, Inc., Lilly USA, LLC, Incyte Corporation, Pharmacyclics, Genzyme, DOVA/SOBI, Exelixis, E.R. Squibb & Sons, L.L.C., AstraZeneca Pharmaceuticals, Sanofi, Daichi Sancho, Morphosys, Regeneron, Glaxo Oncology, CTI, Blue Medicines, Stemline, Taiho, Coherus, Pfizer, Beigene, and Syndax Pharmaceuticals, and on the advisory board and as a consultant for Omeros, Array Biopharma, Inc., Lilly Oncology, Janssen, Epizyme, TG Therapeutics, Regeneron, Abbvie, Takeda, Sanofi, Ipsen, Genentech, Taiho, Abbvie, and Exelixis

Sumana Devata, MD owns stock in Novo Nordisk, AstraZeneca, Glaxco Smith Kline, Abbvie, J&J, Eli Lilly, Merck, Pfizer, and Bayer.

Ahmet Dogan, MD, PhD receives institutional research funding from AstraZeneca and Roche.

Adam DuVall, MD, MPH serves as a consultant for Aptitude Health and Novartis.

Andrew Evens, DO, MBA, MSc serves on the research and advisory board for Pfizer, Genentech, CRISPR Therapeutics, Novartis, Pharmacyclis, and Incyte.

Timothy S. Fenske, MD serves as a consultant for AbbVie, Adaptive Biotechnologies, ADC Therapeutics, Astra Zeneca, Beigene, and Ipsen, and as a speaker for AstraZeneca, Beigene, and SeaGen.

Jacklyn Gideon, MSN, AGPCNP-BC serves on advisory board for Abbvie, Beigene, Genmab, and on the speaker’s bureau Abbvie.

Leo I. Gordon, MD serves on the advisory board for Novartis, BMS and KITE Pharmaceuticals, receives speaker honorarium from BMS and KITE, and serves as an advisor and on the Data and Safety Monitoring Board for Ono Pharmaceuticals.

Gaurav Goyal, MD serves as a consultant for Recordati, and on the advisory board for SeaGen, Electra, and Sobi.

Yasmin H. Karimi, MD serves as a consultant for Abbvie, Merck, and Genentech-Roche and on the advisory board for ADC Therapeutics, AstraZeneca, and GenMab.

Reem Karmali, MD, MS serves on the speaker’s bureau for BeiGene, Astra Zeneca, and BMS and on the advisory board for BMS, GenMab/Abbvie, Kite, and Genentech/Roche. Dr. Karmali plans to discuss the unapproved/investigational use of investigational products in the context of trials and future direction and will disclose the specific trials within the presentation.

Vaishalee P. Kenkre, MD receives institutional funding from ADC Therapeutics, Celgene, Ipsen, MEI Pharma, Inc., and Novartis.

Lori A. Leslie, MD serves as a consultant and on the speaker bureau for Gilead/Kite, AstraZeneca, Beigene, Eli Lilly, Janssen/PCYC, SeaGen, Genmab, and Abbvie, and as a consultant for Crispr and ADCT. Dr. Leslie plans to discuss the unapproved/investigational use of investigational products in evolving fields of btki, bcl2, cart, and bispecifics for p53 abnormal MCL. 

Luis E. Malpica Castillo, MD receives institutional funding from Dizal Pharma.

Neha Mehta-Shah, MD serves as a consultant for Autoious, AstraZeneca, Acrotech, Secura Bio, Ono Pharmaceuticals, Janssen, Kiowa Hakka Kirin, Secura Bio, Daiichi Sankyo, Genetech, Pfizer, Janssen, Morphosys, and Novartis and research funding from Bristol Meyers Squibb, Celgene, Verastem Pharmaceuticals, Innate Pharmaceuticals, Roche/Genetech, Corvus, AstraZeneca, Daichi Sankyo, and C4 Pharmaceuticals.

Lakshmi Nayak, MD serves on the advisory board for Ono Pharmaceuticals, Miltenyi, Curis, and Kite/Gilead and as a consultant for Ono Pharmaceuticals, Curis, Genmab, and BraveBio. Dr. Nayak plans to discuss the unapproved/investigational use of novel therapies under investigation and will disclose the specific therapies within the presentation.

Tycel J. Phillips, MD serves as a consultant for Abbvie, ADCT, AstraZeneca, Beigene, BMS, Caribou, Genmab, Genentech, Gilead, Ipsen, Janssen, Merck, Pharmacyclics, Regeneron, and Xencor, serves on the advisory board for Genmab, Genentech, and Merck, and receives institutional research funding from Abbvie and Genentech. Dr. Phillips plans to discuss the unapproved/investigational use of BTKI.

Priyanka Pophali, MD serves on the advisory board for Seagen, ADC Therapeutics, and Abbvie, as a consultant for Genentech, and receives institutional research funding from Seagen, Fate Therapeutics, and Marker Therapeutics.

Peter Riedell, MD serves on the advisory board for BMS, Kite/Gilead, Novartis, AbbVie, Genmab, Genentech/Roche, BeiGene, and ADC Therapeutics, as a consultant for BMS, AbbVie, Genmab, Genentech/Roche, Pfizer, BeiGene, CVS Caremark, Janssen, and Pharmacyclics, receives speaker honorarium from Adaptive Biotechnologies, and receives institutional research funding from BMS, Kite/Gilead, Novartis, Genentech/Roche, CRISPR Therapeutics, Fate Therapeutics, Cellectis, and Cargo Therapeutics. Dr. Riedell plans to discuss the unapproved/investigational use of BsAB therapy in earlier lines of treatment than current FDA approval.

Nirav N. Shah, MD serves on the advisory board and as a consultant for Gilead-Kite, BMS-Juno, Miltenyi Biomedicine, Lilly Oncology, Incyte, Abbvie, Cargo, Beigene, Kite, Allogene, Astrazeneca, BMS, Ipsen, and Galapagos. Dr. Shah receives institutional research funding and speaker honorarium from Lilly Oncology, Genentech, and Miltenyi Biomedicine. In addition, Dr. Shah is on a scientific advisory board for Tundra Therapeutics.

Sonali Smith, MD serves as a consultant for Genmab, Ono Pharmaceuticals, and Regeneron.

Deborah M. Stephens, DO serves as a consultant Abbvie, AstraZeneca, Beigene, Lilly, Genentech, Pharmacyclics, and BMS, and receives institutional research funding from Abbvie, AstraZeneca, Beigene, Genentech, and BMS. Dr. Stephens plans to discuss the unapproved/investigational use of the combination of BCL2/BTKi/ +/- anti-CD20 in frontline therapy of CLL

Pallawi Torka, MD serves as a consultant for Genmab, Genentech, Pfizer, Abbvie, BMS, and Seagen. Dr. Torka plans to discuss the unapproved/investigational use of recent data presented in conferences about bispecific antibodies.

The staff of the Center for Continuing Medical Education and BioAscend have disclosed that they have no relevant financial relationships with ACCME defined commercial interests.

All relevant financial relationships listed for these individuals have been mitigated.

DISCLAIMER 

The views expressed in this activity are those of the individual speaker. It should not be inferred or assumed that they are expressing the views of any pharmaceutical or product/device manufacturer, provider of commercial services, or The University of Chicago. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication. This is particularly important when a drug is new or infrequently prescribed.

Copyright © 2025 University of Chicago. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from The University of Chicago Center for Continuing Medical Education.